Recent

% | $
Quotes you view appear here for quick access.

Biogen Inc. Message Board

  • brucejohnson824 brucejohnson824 Nov 6, 2013 5:18 PM Flag

    good news

    Gazyva -- a potential blockbuster treatment for previously untreated chronic lymphocytic leukemia, or CLL -- was recently approved by the Food and Drug Administration, marking the company's fifth cancer treatment approval in the U.S. over the past three years. Gazyva was discovered by Roche's wholly owned subsidiary, Glycart. In the United States, the drug is part of a collaboration between its subsidiary Genentech and Biogen (NASDAQ: BIIB ) .

 
BIIB
309.82-2.76(-0.88%)4:00 PMEDT